XTX Topco Ltd Buys New Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA)

XTX Topco Ltd purchased a new position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 44,267 shares of the biopharmaceutical company’s stock, valued at approximately $58,000.

Several other hedge funds have also recently modified their holdings of AKBA. Mercer Global Advisors Inc. ADV grew its stake in shares of Akebia Therapeutics by 40.7% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,221 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 9,037 shares in the last quarter. MetLife Investment Management LLC grew its holdings in Akebia Therapeutics by 25.7% during the 3rd quarter. MetLife Investment Management LLC now owns 68,064 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 13,907 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Akebia Therapeutics by 205.8% in the third quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 31,137 shares during the last quarter. SG Americas Securities LLC bought a new stake in Akebia Therapeutics in the second quarter worth about $34,000. Finally, Empirical Asset Management LLC bought a new stake in shares of Akebia Therapeutics during the 3rd quarter worth approximately $44,000. Hedge funds and other institutional investors own 33.92% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on AKBA. HC Wainwright reiterated a “buy” rating and issued a $7.50 target price on shares of Akebia Therapeutics in a research note on Wednesday, October 23rd. StockNews.com raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 13th.

Akebia Therapeutics Trading Up 2.2 %

NASDAQ AKBA opened at $1.83 on Monday. The firm’s fifty day simple moving average is $1.80 and its two-hundred day simple moving average is $1.46. Akebia Therapeutics, Inc. has a 12-month low of $0.80 and a 12-month high of $2.48. The firm has a market capitalization of $399.27 million, a P/E ratio of -7.96 and a beta of 0.70.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The business had revenue of $37.43 million during the quarter, compared to analyst estimates of $45.66 million. During the same quarter in the previous year, the firm posted ($0.08) EPS. As a group, sell-side analysts predict that Akebia Therapeutics, Inc. will post -0.24 earnings per share for the current fiscal year.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.